Department of Obstetrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Department of Midwifery Science, VU University Medical Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Am J Obstet Gynecol. 2024 Aug;231(2):244.e1-244.e18. doi: 10.1016/j.ajog.2023.12.008. Epub 2023 Dec 12.
Noninvasive prenatal testing by cell-free DNA analysis is offered to pregnant women worldwide to screen for fetal aneuploidies. In noninvasive prenatal testing, the fetal fraction of cell-free DNA in the maternal circulation is measured as a quality control parameter. Given that fetal cell-free DNA originates from the placenta, the fetal fraction might also reflect placental health and maternal pregnancy adaptation.
This study aimed to assess the association between the fetal fraction and adverse pregnancy outcomes.
We performed a retrospective cohort study of women with singleton pregnancies opting for noninvasive prenatal testing between June 2018 and June 2019 within the Dutch nationwide implementation study (Trial by Dutch Laboratories for Evaluation of Non-Invasive Prenatal Testing [TRIDENT]-2). Multivariable logistic regression analysis was used to assess associations between fetal fraction and adverse pregnancy outcomes. Fetal fraction was assessed as a continuous variable and as <10th percentile, corresponding to a fetal fraction <2.5%.
The cohort comprised 56,110 pregnancies. In the analysis of fetal fraction as a continuous variable, a decrease in fetal fraction was associated with increased risk of hypertensive disorders of pregnancy (adjusted odds ratio, 2.27 [95% confidence interval, 1.89-2.78]), small for gestational age neonates <10th percentile (adjusted odds ratio, 1.37 [1.28-1.45]) and <2.3rd percentile (adjusted odds ratio, 2.63 [1.96-3.57]), and spontaneous preterm birth from 24 to 37 weeks of gestation (adjusted odds ratio, 1.02 [1.01-1.03]). No association was found for fetal congenital anomalies (adjusted odds ratio, 1.02 [1.00-1.04]), stillbirth (adjusted odds ratio, 1.02 [0.96-1.08]), or neonatal death (adjusted odds ratio, 1.02 [0.96-1.08]). Similar associations were found for adverse pregnancy outcomes when fetal fraction was <10th percentile.
In early pregnancy, a low fetal fraction is associated with increased risk of adverse pregnancy outcomes. These findings can be used to expand the potential of noninvasive prenatal testing in the future, enabling the prediction of pregnancy complications and facilitating tailored pregnancy management through intensified monitoring or preventive measures.
无细胞游离 DNA 分析的无创性产前检测已在全球范围内提供给孕妇,以筛查胎儿非整倍体。在无创性产前检测中,母体循环中无细胞游离 DNA 的胎儿比例作为质量控制参数进行测量。鉴于胎儿游离 DNA 源自胎盘,胎儿比例也可能反映胎盘健康和母体妊娠适应情况。
本研究旨在评估胎儿比例与不良妊娠结局之间的关联。
我们对 2018 年 6 月至 2019 年 6 月期间在荷兰全国实施研究(荷兰实验室评估非侵入性产前检测试验[TRIDENT]-2)中选择进行无创性产前检测的单胎妊娠妇女进行了回顾性队列研究。多变量逻辑回归分析用于评估胎儿比例与不良妊娠结局之间的关联。胎儿比例被评估为连续变量和<第 10 百分位数,对应于胎儿比例<2.5%。
该队列包括 56110 例妊娠。在分析胎儿比例作为连续变量时,胎儿比例下降与妊娠高血压疾病的风险增加相关(调整后的优势比,2.27[95%置信区间,1.89-2.78])、小于胎龄儿<第 10 百分位数(调整后的优势比,1.37[1.28-1.45])和<第 2.3 百分位数(调整后的优势比,2.63[1.96-3.57])以及 24 至 37 孕周自发性早产(调整后的优势比,1.02[1.01-1.03])相关。未发现胎儿先天性畸形(调整后的优势比,1.02[1.00-1.04])、死胎(调整后的优势比,1.02[0.96-1.08])或新生儿死亡(调整后的优势比,1.02[0.96-1.08])存在相关性。当胎儿比例<第 10 百分位数时,也发现了与不良妊娠结局相关的类似关联。
在孕早期,低胎儿比例与不良妊娠结局的风险增加相关。这些发现可用于未来扩展无创性产前检测的潜力,通过预测妊娠并发症并通过强化监测或预防措施促进量身定制的妊娠管理,从而实现这一目标。